Neutropenia (Low White Blood Cell Count)
Conditions
Keywords
Filgrastim
Brief summary
This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as neutrophils. This type of white cell is important in fighting infections. A low neutrophil count is known as neutropenia. Both drugs work by increasing the number of neutrophils that are produced in the body. This is important for patients who have low neutrophils due to chemotherapy, other treatments such as bone marrow transplant or certain other conditions with symptoms/problems related to low neutrophil counts. The main aim of the study is to test how Filgrastim Hospira works in the body compared to Neupogen®.
Detailed description
This is a randomized, open-label, single-dose, two-way crossover study evaluating the PK and PD equivalence following SC administration of test and reference product in healthy volunteers. The study will be conducted at a single Phase 1 unit. After meeting the selection criteria, subjects will be randomly assigned to 1 of the 2 treatment sequences: * Filgrastim Hospira (US) followed by US-approved Neupogen® * US-approved Neupogen® followed by Filgrastim Hospira (US) Subjects will receive one of the drugs in the first Period and the other drug in the other Period.
Interventions
BIOLOGICALFilgrastim Hospira (US)
5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
BIOLOGICALUS-approved Neupogen®
5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
Sponsors
Hospira, now a wholly owned subsidiary of Pfizer
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provides written informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB) prior to any study related activities 2. Healthy male or female volunteers between 18 and 65 years of age (both inclusive) 3. Body mass index (BMI) between 19 and 30 kg/m2, inclusive, and body weight of not \< 50 kg or \> 100 kg 4. Non smoker (defined as a subject who has not smoked and has not used nicotine containing products for at least 3 months prior to study drug administration and has a negative urine screen for cotinine) at Screening 5. Female subjects of childbearing potential, and male subjects and their partners of childbearing potential, agree to pregnancy prevention throughout the duration of the study (through the Final Visit). Subjects and their partners must agree to use of an effective method of contraception, to avoid impregnation of females throughout the course of the study. Subjects using oral contraceptives must be on a stable regimen for at least 3 months prior to Screening. While the best way to avoid pregnancy is to abstain from sexual activity, adequate forms of contraception to be used include oral contraception, depot contraception, intrauterine device (IUD), and barrier contraceptive methods, such as condoms and barrier creams/contraceptive jellies, and spermicidals. Subjects and their partners who can become pregnant must use contraception while on study drug from admission to the Final Visit. Male subjects must also refrain from donating sperm from admission to the Final Visit 6. Agrees to abstain from alcohol consumption throughout duration of the study and has a negative urine for alcohol at Screening
Exclusion criteria
1. Any active systemic or immunologic disease or condition, including but not limited to the following general categories: cardiovascular/pulmonary, hepatorenal, or systemic infection, or lactation 2. Hematologic laboratory abnormalities including leukocytosis (defined as total leukocytes \> 11,000/µL), leukopenia (defined as total leukocytes \< 4000/μL), or neutropenia (defined as absolute neutrophil count \[ANC\] \< 1500/µL) or thrombocytopenia (defined as platelet count of \< 150/µL) 3. Clinically significant, as judged by the Investigator, vital sign, chest X-ray, or 12-lead ECG abnormality 4. History of biological growth factor exposure, including but not limited to filgrastim and other G-CSFs in the context of treatment, prophylaxis, peripheral blood stem cell mobilization, or previous investigational study setting 5. Drug sensitivity, allergic reaction to, or known hypersensitivity/idiosyncratic reaction to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, other granulocyte colony-stimulating factors or any component of the product. Subjects with the rare heredity problem of fructose intolerance are excluded due to the excipient sorbitol 6. History of splenic rupture (or subject who is asplenic), pulmonary infiltrate or pneumonia, sickle cell disease, chronic neutropenia, thrombocytopenia, or vasculitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the serum filgrastim concentration versus time curve from zero to infinity (AUC0-∞) | 1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration |
| Maximum serum filgrastim concentration (Cmax) | 1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration |
| Area under the effect curve for Absolute Neutrophil Count (ANC) (AUEC ANC) | 1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration |
| Maximum observed ANC ( ANC max) | 1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration |
Secondary
| Measure | Time frame |
|---|---|
| Time to maximum serum filgrastim concentration (Tmax) | 1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration |
| Elimination half-life (t ½) | 1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration |
| Area under the serum filgrastim concentration versus time curve from time zero to the time of the last measurable concentration versus time curve from time zero to the time of the last measurable concentration (AUC0-t) | 1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration |
| Clearance (CL) | 1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration |
| Time to maximum ANC (Tmax[ANC]) | 1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration |
| Volume of distribution (Vd) | 1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration |
Countries
United States
Outcome results
None listed